American Association for Cancer Research
00085472can112536-sup-f1_2132k.pdf (2.08 MB)

Supplementary Figure 1 from Fra-1 Promotes Breast Cancer Chemosensitivity by Driving Cancer Stem Cells from Dormancy

Download (2.08 MB)
journal contribution
posted on 2023-03-30, 21:13 authored by Dan Lu, Si Chen, Xiaoyue Tan, Na Li, Chenghu Liu, Zongjin Li, Ze Liu, Dwayne G. Stupack, Ralph A. Reisfeld, Rong Xiang

PDF file - 2.1MB, Human breast cancer cells were treated with CTX (500uM) for 24hrs and the apoptosis were evaluated by Annexin V and PI double staining (A). Fra-1 expression in these breast cancer cells were detected by Western-blot (B)



Fra-1 is a member of the Fos transcription factor family that is highly expressed in multiple cancers, playing important roles in transformation, proliferation, and metastasis. In this study, we observed an inverse correlation between the expression of Fra-1 in human stage II breast cancer tissues and the corresponding level of clinical chemoresistance. Extending these findings in vitro, we found that knockdown of Fra-1 in breast tumor cells was sufficient to confer resistance to doxorubicin and cyclophosphamide, whereas enhanced Fra-1 expression could render these cells chemosensitive. The tumor cell side population, which is enriched for cancer stem cells, was found to be associated with chemoresistance. Increased side population fractions were detected among tumor cell lines subjected to Fra-1 knockdown. In contrast, enhanced expression of Fra-1 was correlated with a decreased side population fraction, and significantly, this finding was recapitulated in vivo, where tumors with enhanced expression of Fra-1 were found to have blunted growth. Tumor cells subjected to Fra-1 knockdown grew faster and were larger in size. Taken together, our findings suggest that Fra-1 may be an important prognostic marker for breast cancer therapy. Cancer Res; 72(14); 3451–6. ©2012 AACR.

Usage metrics

    Cancer Research



    Ref. manager